KIF6 Genotype

About six in ten people of European ancestry carry the variant this test reports. For a few years it looked like the most useful genetic fact in cardiology: carriers seemed to have more heart attacks, and seemed to get far more out of a statin. Then much larger studies went looking for the same effect and could not find it.

So what this test gives you is a clean answer to a question that still circulates in older cardiac gene panels and consumer reports. You get your genotype, and you get to stop weighing it in decisions where the evidence says it does not belong.

What the Gene Makes

KIF6 (kinesin family member 6) codes for a motor protein. Motors in this family walk along the internal scaffolding of a cell and haul cargo from one end to the other. The variant that made the gene famous, written Trp719Arg or rs20455, swaps tryptophan for arginine at position 719 of that protein. The arginine version is the one that was called higher risk.

Nobody ever showed what that swap does to a blood vessel. The trials that reported a benefit concluded the effect ran through something other than cholesterol or inflammation, and left it there. A gene association with no mechanism behind it isn't automatically wrong, but it is fragile, and this one broke.

Heart Attack and Coronary Risk

The first results were striking. In the placebo arms of two statin trials, carriers had roughly 50% more coronary events than noncarriers. In the Women's Health Study, which followed 25,283 women, carriers had about a third more heart attacks and about a quarter more coronary heart disease after adjusting for the usual risk factors.

Pooling the early prospective work gave a similar answer. Across eight studies and 77,400 people, carrier risk came out modestly higher, around 27%. In the same report, pooling case-control studies instead showed no excess risk at all, and the individual studies disagreed with each other badly. That split was the first sign of trouble.

Then came the studies built specifically to test the claim.

Sources: Heart Protection Study (Hopewell et al.); Assimes et al.; Li et al.

What this means for you: if a report has told you that you carry a higher-risk version of this gene, the largest body of evidence says your coronary risk is whatever your cholesterol, blood pressure, plaque, and family history say it is. This variant doesn't move that estimate enough to change anything you would do.

The early work was almost entirely in people of European ancestry. In a Costa Rican study of 4,134 people, carrying the variant was not significantly associated with nonfatal heart attack once other risk factors were accounted for. Among 924 Han Chinese adults undergoing angiography, the variant was not an independent predictor of coronary disease, though carriers ran somewhat higher triglycerides.

Why the Early Findings and the Later Ones Disagree

Two sets of honest studies pointing in opposite directions usually means one of them was reading noise. The tell here is the direction of travel: the association shrank as the samples grew, and disappeared in the studies designed to test it rather than to find it. Early signals came largely from subgroups inside trials run for other purposes, where a modest effect can turn up by chance and then get published because it's interesting. The later work asked one pre-specified question of tens of thousands of people and got an answer near zero.

The picture is not uniformly blank, and it's worth being precise about what survived. Pooled prospective cohorts still show a small excess in carriers, and a 2018 pooling of seven studies covering 48,885 people taking statins found carriers had roughly 25% higher odds of a major cardiovascular event than noncarriers. Prospective cohorts are also where the original signal came from, so pooling them carries that bias forward, and the case-control data pooled across more than 100,000 people show nothing. What has not survived anywhere is the treatment claim: statins cut events by the same amount in every genotype.

This is the ordinary life cycle of a candidate gene. It doesn't mean the first investigators did anything wrong, and it doesn't mean some future study will rescue the finding. It means the burden of proof was never met.

Statin Benefit

The more interesting early claim was about treatment, not risk. After an acute coronary syndrome, in 1,778 people, carriers got a large benefit from intensive statin therapy compared with moderate therapy while noncarriers got essentially none. In 5,752 older adults, carriers with existing vascular disease appeared to benefit from pravastatin and noncarriers did not, though the difference between genotypes did not reach statistical significance.

The Heart Protection Study settled it. Among 18,348 people randomly assigned to simvastatin or placebo, the drug cut major vascular events by 23% in carriers and 24% in noncarriers, and lowered LDL cholesterol by about 42% in both. The same null result appeared in 1,255 people with diabetes on dialysis given atorvastatin, and a later analysis of the elderly trial concluded the genotype did not predict who benefited.

The practical consequence is simple. This genotype has no place in a decision about whether to take a statin or how hard to push. That decision runs on your ApoB, LDL cholesterol, blood pressure, and whether you already have plaque. ApoB counts the cholesterol-carrying particles circulating in your blood, which is the thing doing the damage.

Cholesterol, Triglycerides, and Waist Size

Smaller studies have found the variant tracking with things other than events. In 1,622 adults in an Italian cohort, it was associated with lipid patterns and abdominal obesity in men, and not with how well statins worked. In a small Spanish study, people carrying two copies of the Arg version had about a 7% smaller drop in LDL cholesterol on statins, a difference the 18,348-person randomized trial did not reproduce.

Contrast Dye and the Kidneys

One finding has not been tested again. Among 1,253 people undergoing coronary angiography or stenting, those with two copies of the Arg version had more contrast-induced nephropathy. That means kidney function dropping in the days after the dye used for the procedure. The association showed up only in people not already taking a statin.

A single cohort with a subgroup result is roughly where the coronary story started. Treat it as a hypothesis, not a reason to change anything about a planned procedure.

A Different Variant, and Sperm

Sequencing the whole gene can turn up more than position 719. A separate variant, rs2273063, appeared in 87.5% of men with unexplained infertility and in none of the fertile controls in a Taiwanese study that sequenced the protein-coding parts of the genome. Follow-up sequencing found mutations in this gene in 65% of the infertile men against 13% of fertile men. Later laboratory work, done in cells and animals rather than in people, showed the protein helping to assemble the sperm tail, which gives that finding a mechanism the coronary story never had.

Hold it lightly anyway. It is one small cross-sectional study in one population, and the variant runs at about 25% in East Asian populations against about 4% worldwide, so frequency alone will skew small samples. It is also not the variant the cardiology literature is about, and the two should never be discussed as if they were the same result.

What Your Ancestry Changes

Carrier frequency varies enormously by population, which changes what a positive result even means. About 60% of people of European ancestry carry at least one copy of the 719Arg version, and it is common among Filipino-American women as well. A version carried by six in ten people can still nudge risk, but it will never be the thing that separates one person's future from another's.

Reference databases also underrepresent non-European populations. If your ancestry is one of them, broad gene sequencing is more likely to return a change nobody can classify yet: roughly 15% to 20% of people from underrepresented groups get one, against about 10% in European cohorts.

When Results Can Be Misleading

• What the assay covers: sequencing reports only the regions it targets. A call at position 719 says nothing about the rest of the gene, and across clinical testing roughly one in seven disease-causing variants are hard for short-read sequencing to detect at all.
• Unclassified findings: whole-gene sequencing can return a change with no known meaning. That is not a diagnosis, and on its own it is not a reason to start a workup.
• Two reports, two answers: research sequencing and clinical genotyping agree almost all the time, and the rare mismatches trace back to sample switches or to one copy of a gene failing to amplify. If a consumer report and a clinical lab disagree, work from the clinical lab's call.

This Is a One-Time Result

Your genotype will read the same at 40 and at 70. There is nothing to track here and no reason to repeat the test unless the lab flags a low-confidence call. The tracking belongs to the markers that actually move.

Get a baseline ApoB and lipid panel now, repeat in 3 to 6 months while you are changing anything, then at least annually. Measure Lp(a) once. It is an inherited particle that raises heart attack risk, it barely responds to diet, and it is largely fixed for life. Add hs-CRP to the baseline and follow it on the same schedule. It picks up low-grade inflammation.

What to Do With the Result

If you're a carrier, which most people of European ancestry are, the right response is to change nothing on account of it and to make sure the rest of your cardiovascular picture is measured rather than guessed. That means ApoB instead of LDL alone, Lp(a) once, blood pressure, and, past about 40 with any risk factors, a coronary calcium scan to find out whether plaque exists.

If early heart disease runs in your family and standard lipids look ordinary, the workup is inherited cholesterol disorders, Lp(a), and a polygenic score that sums hundreds of small genetic effects. A lipid specialist or genetic counselor can run that and tell you which relatives should be tested for what.

If sequencing returns an unexpected variant in this gene and you are already being evaluated for infertility, mention it to the specialist running that workup. The evidence there is one small study, so it is something to add to a picture, not a diagnosis.